AstraZeneca, Daiichi Sankyo gets Chinese nod for Enhertu as first HER2-directed therapy for patients with HER2-low metastatic breast cancer Ruchika Sharma16 July 2023 1:00 PM ISTEnhertu is a HER2-directed ADC.
AstraZeneca Xigduo XR approved in China for adults with type 2 diabetes Ruchika Sharma28 Jun 2023 4:30 PM ISTChina: AstraZeneca’s Xigduo XR (dapagliflozin and metformin hydrochloride extended-release), a once-daily fixed-dose combination, has been approved by...
AstraZeneca Soliris recommended for nod in EU by CHMP for children, adolescents with refractory generalised myasthenia gravis Ruchika Sharma26 Jun 2023 4:37 PM ISTSoliris is a first-in-class C5 complement inhibitor.
AstraZeneca planning to spin off China business: Report Ruchika Sharma22 Jun 2023 5:33 PM ISTThe spin off could protect AstraZeneca from tensions between China and other global powers, while the company retained control of the business, the...
AstraZeneca switching to biogas to cut US carbon footprint Ruchika Sharma15 Jun 2023 1:30 PM ISTLondon: Drugmaker AstraZeneca is switching to biogas produced from cow manure and food waste in the United States, it said on Tuesday, in a...
AstraZeneca Soliris approved in China for adults with refractory generalised myasthenia gravis Ruchika Sharma14 Jun 2023 10:00 AM ISTCambridge: AstraZeneca has announced that Soliris (eculizumab) has been approved in China for the treatment of adult patients with refractory...
AstraZeneca, Quell Therapeutics ink pact for engineered T-regulatory cell therapies for autoimmune diseases Ruchika Sharma11 Jun 2023 10:30 AM ISTQuell will receive USD 85 million upfront from AstraZeneca, which comprises a predominant cash payment and an equity investment.
USFDA nod to AstraZeneca, MSD's Lynparza plus Abiraterone and Prednisone or Prednisolone for BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer Ruchika Sharma2 Jun 2023 3:30 PM ISTRahway: AstraZeneca and Merck, known as MSD outside of the United States and Canada, has announced that LYNPARZA in combination with abiraterone...
AstraZeneca discontinues brazikumab inflammatory bowel disease development programme Ruchika Sharma2 Jun 2023 1:30 PM ISTCambridge: AstraZeneca has announced the discontinuation of the brazikumab inflammatory bowel disease (IBD) development programme, an anti-IL-23...
CDSCO nod to AstraZeneca cancer drug Tremelimumab Ruchika Sharma2 Jun 2023 11:53 AM ISTThe approval paves the way for the launch of Tremelimumab solution of 20 mg/ml (25 mg/1.25 ml and 300 mg/15 ml presentations in single-dose vials) in...
AstraZeneca Ultomiris gets Japanese nod for prevention of relapses in patients with neuromyelitis optica spectrum disorder Ruchika Sharma28 May 2023 11:00 AM ISTNMOSD is a rare and debilitating autoimmune disease that affects the central nervous system, including the spine and optic nerves.
AstraZeneca to leave leading US drug lobby group Ruchika Sharma17 May 2023 1:30 PM ISTAstraZeneca's exit follows those of AbbVie, maker of blockbuster arthritis drug Humira, and Teva, a leading manufacturer of generic drugs.
